Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Belgium: Megace; Bulgaria: Megace; Czech Republic: Megace, Megaplex; Denmark: Megace; Finland: Megace; France: Megace; Germany: Megestat; Greece: Megace; Hungary: Megace, Megesin, Megyrina; Ireland: Megace; Italy: Gestroltex, Megace, Megestil, Megestrolo; Latvia: Megaplex; Lithuania: Megace; Luxembourg: Megace; Netherlands: Megace, Megestrolacetaat; Poland: Cachexan, Gestar, Gestrol, Megace, Megalia, Megesin; Portugal: Acestrol, Megace, Megestrol; Romania: Lutenyl, Megesin; Slovakia: Megace, Megaplex, Megesin; Slovenia: Megace; Spain: Borea, Maygace, Megefren; Sweden: Megace; UK: Megace.

North America

Canada: Megace, Megestrol; USA: Megace, Megestrol.

Latin America

Argentina: Megestrol, Varigestrol; Brazil: Femigestrol, Gynodal, Megestat; Mexico: Megace, Mestrel.

Drug combinations


Megestrol Acetate: C~24~H~32~O~4~. Mw: 384.51. (1) Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-; (2) 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate. CAS-595-33-5; CAS-3562-63-8 (megestrol)(1963).

Pharmacologic Category

Antineoplastic Agents; Endocrine Therapy; Hormone. Hormones and Synthetic Substitutes; Progestins. Appetite Stimulant. Progestin. (ATC-Code: G03AC05; G03DB02; L02AB01).

Mechanism of action

Megestrol is an antineoplastic progestin thought to act through antileutenizing effect mediated via pituitary. May stimulate appetite by antagonizing metabolic effects of catabolic cytokines.

Therapeutic use

Palliative treatment of breast and endometrial carcinoma. Treatment of anorexia, cachexia, or unexplained significant weight loss in AIDS.

Pregnancy and lactiation implications

Adverse effects demonstrated in animal studies. Use during pregnancy contraindicated (suspension). HIV-infected mothers are discouraged from breast-feeding to decrease potential transmission of HIV.

Unlabeled use


Hypersensitivity to megestrol or any component of the formulation. Pregnancy (suspension).

Warnings and precautions

Hazardous agent. Might suppress hypothalamic-pituitary-adrenal axis during chronic administration. New-onset diabetes mellitus and exacerbation of pre-existing diabetes reported with long-term use. Use with caution in history of thromboembolic disease. Vaginal bleeding or discharge might occur.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart